NIH Grants Exclusive License for Autoimmune CAR Therapy
Published Date: 2/13/2026
Notice
Summary
The National Cancer Institute plans to give Kyverna Therapeutics an exclusive license to use a special CAR therapy that helps treat or prevent autoimmune diseases caused by B cells. This means Kyverna will be the only company allowed to develop and sell this innovative treatment. If you want to comment or apply for a license, you need to act by March 2, 2026.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Exclusive License to Kyverna for Anti‑CD19 CARs
The National Cancer Institute is contemplating granting Kyverna Therapeutics an exclusive patent license (which may be worldwide) for developing, producing, and commercializing an anti‑CD19 CAR immunotherapy that uses either a non‑viral synthetic nanoparticle system or a viral system (excluding lentiviral) that encapsulates mRNA or DNA encoding a CAR with the Hu19 CDR sequences, for the treatment or prevention of B cell mediated autoimmune diseases.
Deadline to Comment or Apply for License
If you want to comment on or apply for this exclusive license, written comments and/or license applications must be received by the NCI Technology Transfer Center on or before March 2, 2026. License applications filed in response to this notice will be treated as objections to the grant and are presumed to contain business confidential information.
Field of Use Carve-Outs and Royalty Requirement
The contemplated exclusive license would exclude anti‑CD19 CAR approaches that use CRISPR/Cas9‑edited allogeneic T lymphocytes and autologous T lymphocytes engineered by lentivirus, and it does not include CAR constructs that exclusively use the FMC63 antigen binding domain. The prospective exclusive license will be royalty bearing.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in